Where Retatrutide Fits in the GLP-1 Drug Tree

If you're trying to make sense of retatrutide — Eli Lilly's next-generation obesity drug in late-stage clinical trials — the clearest way to understand it is to see it as the latest branch on a tree that's been growing for more than two decades. Each generation of GLP-1 drugs extends the reach of the one before it. Retatrutide extends the reach of tirzepatide.

Here's how the incretin drug tree grew.

The Trunk: GLP-1 Biology

Before the drugs, the biology. Your gut produces a hormone called glucagon-like peptide-1 (GLP-1) after you eat. GLP-1 tells the pancreas to release insulin, slows down gastric emptying, and sends fullness signals to your brain.

The problem: natural GLP-1 lasts about 2 minutes in your bloodstream before enzymes break it down. For it to work as a drug, scientists needed to engineer a version that sticks around much longer — days to weeks — while still activating the same receptors.

That engineering project produced the GLP-1 receptor agonist class. Everything on this drug tree is a synthetic peptide (or small molecule, in more recent research) that binds to GLP-1 receptors — and some bind to additional receptors as well.

Generation 1: Exenatide (Byetta, Bydureon) — 2005

Exenatide was the first GLP-1 receptor agonist to reach patients. It was derived from a protein in the Gila monster's saliva — exendin-4 — that happened to activate GLP-1 receptors with significantly longer duration than human GLP-1.

• Target: GLP-1 receptor only
• Half-life: ~2.4 hours (twice-daily injection for Byetta; extended-release for Bydureon)
• Primary use: Type 2 diabetes
• Weight loss: Modest, roughly 2–3 kg over 6 months in trials

Exenatide proved the concept. GLP-1 receptor agonism in humans produced exactly the effects the biology predicted: lower blood sugar, slower gastric emptying, less appetite. The side-effect profile — mainly nausea — also appeared at this stage. But the weight loss was underwhelming for many patients, and the injection frequency was a barrier.

Generation 2: Liraglutide (Victoza, Saxenda) — 2010

Liraglutide was the first GLP-1 agonist engineered for human GLP-1 structure (rather than derived from another species). Novo Nordisk modified the peptide to bind to albumin in the bloodstream, dramatically extending its half-life.

• Target: GLP-1 receptor only
• Half-life: ~13 hours (daily injection)
• Primary use: Type 2 diabetes (Victoza, 2010); weight management (Saxenda, 2014)
• Weight loss: Roughly 5–8% of body weight over 56 weeks in SCALE trials

Liraglutide was the first GLP-1 agonist with a dedicated FDA-approved obesity indication. Weight loss was real but moderate by modern standards. The daily injection remained a barrier. But SCALE established the proof of concept for GLP-1 agonism in obesity treatment specifically.

Generation 3: Semaglutide (Ozempic, Wegovy, Rybelsus) — 2017

Semaglutide is the drug that changed the market. Novo Nordisk's engineers extended liraglutide's half-life further by adding a longer fatty acid chain, achieving weekly dosing.

• Target: GLP-1 receptor only
• Half-life: ~7 days (once-weekly injection; 24 hours for oral Rybelsus)
• Primary use: Type 2 diabetes (Ozempic, 2017); weight management (Wegovy, 2021)
• Weight loss: ~14.9% mean body weight at 68 weeks (STEP-1 trial, 2.4 mg)

The jump from liraglutide to semaglutide wasn't just about injection frequency. The weight loss efficacy roughly doubled. STEP-1 results landed in the media not as a clinical footnote but as a genuine cultural moment — a drug that produced weight loss in the range of bariatric surgery for many patients.

The oral formulation (Rybelsus) was a separate engineering feat: coating the peptide in a carrier (SNAC) that protects it from digestion. It never achieved the same efficacy as the injectable at equivalent doses, but it opened the market to needle-averse patients.

The Branch Point: Dual Agonism

The next leap didn't come from engineering a better GLP-1 agonist. It came from asking: what if we targeted a second receptor at the same time?

Your gut secretes other incretin hormones, not just GLP-1. One of them — GIP (glucose-dependent insulinotropic polypeptide) — also influences insulin secretion, fat storage, and energy metabolism. GLP-1 and GIP work through different mechanisms but have complementary effects on weight and metabolism.

Could a molecule that activates both do more than either alone?

Generation 4: Tirzepatide (Mounjaro, Zepbound) — 2022

Tirzepatide answered that question. Eli Lilly's dual GIP/GLP-1 receptor agonist is a single peptide that activates both receptors, engineered with a fatty acid modification for once-weekly dosing.

• Targets: GIP receptor + GLP-1 receptor (dual agonist)
• Half-life: ~5 days (once-weekly injection)
• Primary use: Type 2 diabetes (Mounjaro, 2022); weight management (Zepbound, 2023)
• Weight loss: Up to 22.5% mean body weight at 72 weeks (SURMOUNT-1, 15 mg dose)

The SURPASS and SURMOUNT trial results confirmed that dual agonism outperforms single GLP-1 agonism on weight loss. Exactly how GIP contributes is still debated — the receptor may work somewhat differently in obese vs. lean individuals — but the clinical outcome data is unambiguous.

The pattern is clear. More targets, more weight loss.

Generation 5: Retatrutide — In Trials

Retatrutide (Eli Lilly, LY3437943) takes the dual agonism of tirzepatide and adds a third receptor target: the glucagon receptor.

• Targets: GLP-1 receptor + GIP receptor + glucagon receptor (triple agonist)
• Half-life: ~6 days (once-weekly injection, in trials)
• Primary use: Obesity, type 2 diabetes (TRIUMPH phase 3 trials)
• Phase 2 weight loss: ~24.2% mean body weight at 48 weeks (highest dose, NEJM 2023)

Adding glucagon receptor agonism introduces a new mechanism. Glucagon normally raises blood sugar — it's the counter-regulatory hormone to insulin. Activating glucagon receptors also increases energy expenditure (thermogenesis) and drives fat breakdown in the liver. By co-activating glucagon alongside GLP-1 and GIP, retatrutide adds an energy-expenditure component that the earlier drugs lack.

Why doesn't glucagon receptor activation raise blood sugar in this context? The GLP-1 component suppresses the insulin-opposing effects of glucagon — insulin secretion goes up while the glucagon-driven glucose release is blunted. The net effect on blood sugar is controlled, while the fat-burning and thermogenic effects of glucagon activation carry through.

Retatrutide vs. Semaglutide vs. Tirzepatide

Two caveats on the weight loss comparison: the phase 2 trial for retatrutide was at 48 weeks (shorter than the STEP-1 and SURMOUNT-1 trials), and phase 2 participants are often more highly selected than phase 3. Phase 3 TRIUMPH results will tell us whether the superiority holds in a broader population.

What Comes After Triple Agonism?

The drug tree doesn't stop at retatrutide. Several other approaches are in early development:

Oral GLP-1 agonists beyond Rybelsus. Pfizer's danuglipron and others are small-molecule oral GLP-1 agonists — not peptides. They offer daily-pill dosing rather than weekly injection. Efficacy has been mixed in early trials, but the delivery advantage is real.

Amylin agonists. Cagrilintide (Novo Nordisk) activates amylin receptors and is being developed in combination with semaglutide. The REDEFINE trials showed roughly 22% weight loss with the combo at 68 weeks — competitive with tirzepatide.

GLP-1/glucagon dual agonists (without GIP). Several are in trials, exploring whether the thermogenic effect of glucagon plus GLP-1 matches tirzepatide's GIP/GLP-1 combination.

The direction of travel is toward combination therapies that hit multiple metabolic pathways simultaneously — the same logic that drove retatrutide's design.

Why This History Matters for Patients

If you're deciding between available drugs today (semaglutide and tirzepatide) or waiting for retatrutide, the evolutionary chart offers a frame for the trade-offs:

• More targets means more weight loss efficacy in trials — but also more complexity and potentially a different side-effect profile
• Tirzepatide's GI side effects are broadly similar to semaglutide's but some patients report differences in specific symptoms
• Retatrutide's glucagon receptor component adds a new variable: potential effects on liver fat, thermogenesis, and glucose dynamics that don't have long trial histories
• The first drug that works for you may not be the newest one on the tree

The drug that produces the best outcome for a given person is the one they tolerate, stay on, and pair with sustainable habits. Retatrutide's early efficacy numbers are striking. Phase 3 data will tell us whether those numbers survive real-world testing.

Related reading

• What is retatrutide?
• Semaglutide guide
• Tirzepatide guide
• Tirzepatide vs. semaglutide
• What are GLP-1 peptides?